NEW YORK (GenomeWeb News) – Roche today reported that sales in its diagnostics division grew 5 percent year over year at constant exchange rates during the first half of 2012 while the molecular diagnostics business grew 6 percent.

For the six months ending June 30, the Swiss drug and diagnostics firm reported diagnostic sales of CHF 5.01 billion ($5.13 billion) compared to CHF 4.86 billion during the first half of 2011. In Swiss francs the division grew 3 percent, and in dollars first-half 2012 sales were up 1 percent year over year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.